|
Trade Name | LIPOSORBER LA-15 System |
Classification Name | apheresis for focal glomerulosclerosis in adult and pediatric patients |
Generic Name | apheresis for focal glomerulosclerosis in adult and pediatric patients |
Applicant |
KANEKA PHARMA AMERICA LLC |
546 fifth ave., 21st floor |
new york, NY 10036 |
|
HDE Number | H120005 |
Supplement Number | S006 |
Date Received | 04/13/2017 |
Decision Date | 05/23/2017 |
Product Code | |
Advisory Committee |
Gastroenterology |
Supplement Type | normal 75 day track |
Supplement Reason | change design/components/specifications/material |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approval for changes to the housing of adsorption column la-15 and connector parts of tubing system nk-m3r(u), plus components of the liposorber® la-15 system. The device, as modified, will be marketed under the trade name liposorber® la-15 system and is indicated for use in the treatment of pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis when:1) standard treatment options, including corticosteroids and/or calcineurin inhibitortreatments, are unsuccessful or not well tolerated and the patient’s glomerular filtrationrate (gfr) >= 60 ml/min/1. 73 m2 or; 2) the patient is post renal transplantation. |